AU2018317372B2 - Novel nicotine-binding antibodies - Google Patents

Novel nicotine-binding antibodies Download PDF

Info

Publication number
AU2018317372B2
AU2018317372B2 AU2018317372A AU2018317372A AU2018317372B2 AU 2018317372 B2 AU2018317372 B2 AU 2018317372B2 AU 2018317372 A AU2018317372 A AU 2018317372A AU 2018317372 A AU2018317372 A AU 2018317372A AU 2018317372 B2 AU2018317372 B2 AU 2018317372B2
Authority
AU
Australia
Prior art keywords
nicotine
seq
sequence
heavy
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018317372A
Other languages
English (en)
Other versions
AU2018317372A1 (en
Inventor
Nicola Beltraminelli
Zuzana Biesova
Stéphanie FALLOT
Steve Fuller
Matthew W. Kalnik
Mark G. LESAGE
Paul PENTEL
Thomas Thisted
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Blink Biomedical SAS
Hennepin Healthcare Research Institute
Antidote Therapeutics Inc
Original Assignee
Blink Biomedical SAS
Hennepin Healthcare Res Institute
Antidote Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blink Biomedical SAS, Hennepin Healthcare Res Institute, Antidote Therapeutics Inc filed Critical Blink Biomedical SAS
Publication of AU2018317372A1 publication Critical patent/AU2018317372A1/en
Assigned to BLINK BIOMEDICAL SAS, Antidote Therapeutics, Inc., Hennepin Healthcare Research Institute reassignment BLINK BIOMEDICAL SAS Amend patent request/document other than specification (104) Assignors: Antidote Therapeutics, Inc., BliNK Biomedical, Hennepin Healthcare Research Institute
Application granted granted Critical
Publication of AU2018317372B2 publication Critical patent/AU2018317372B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018317372A 2017-08-15 2018-08-14 Novel nicotine-binding antibodies Active AU2018317372B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762545696P 2017-08-15 2017-08-15
US62/545,696 2017-08-15
PCT/US2018/046621 WO2019036419A1 (en) 2017-08-15 2018-08-14 NEW NICOTINE BINDING ANTIBODIES

Publications (2)

Publication Number Publication Date
AU2018317372A1 AU2018317372A1 (en) 2020-03-05
AU2018317372B2 true AU2018317372B2 (en) 2025-06-26

Family

ID=63405495

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018317372A Active AU2018317372B2 (en) 2017-08-15 2018-08-14 Novel nicotine-binding antibodies

Country Status (11)

Country Link
US (2) US11440970B2 (enExample)
EP (2) EP4624496A3 (enExample)
JP (1) JP7364555B2 (enExample)
KR (1) KR102712005B1 (enExample)
CN (1) CN111432883B (enExample)
AU (1) AU2018317372B2 (enExample)
BR (1) BR112020002994A2 (enExample)
CA (1) CA3072767A1 (enExample)
ES (1) ES3041362T3 (enExample)
MX (1) MX2020001725A (enExample)
WO (1) WO2019036419A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512549A (zh) * 2018-06-06 2021-03-16 安蒂多特疗法公司 改善循环和治疗心血管疾病的方法
KR102530111B1 (ko) * 2022-03-11 2023-05-10 앱클론(주) 코티닌을 표적하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이들의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194158A2 (en) * 1985-03-08 1986-09-10 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2002251821A1 (en) 2001-01-26 2002-08-06 The Scripps Research Institute Nicotine immunogens and antibodies and uses thereof
WO2003082329A2 (en) 2002-03-01 2003-10-09 The Board Of Regents Of The University Of Nebraska Compositions and compounds for use as molecular adjuvant for a nicotine vaccine
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US20060111271A1 (en) 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
US8316104B2 (en) * 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
EP1963308A4 (en) 2005-11-28 2010-12-15 Nabi Biopharmaceuticals METHOD FOR PRODUCING A NICOTINE HAPTEN
WO2007100755A1 (en) 2006-02-27 2007-09-07 Nabi Biopharmaceuticals Method for decreasing the toxic effects of nicotine on fetuses in pregnant women
EP2222702B1 (en) * 2007-11-29 2016-01-13 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
EP2065398A1 (en) 2007-11-29 2009-06-03 Cytos Biotechnology AG Human monoclonal nicotine specific antibodies
MX2010013583A (es) 2008-06-13 2011-05-19 Nabi Biopharmaceuticals Kit y metodo para dejar de fumar.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194158A2 (en) * 1985-03-08 1986-09-10 Baylor College of Medicine Anti-nicotine and anti-cotinine antibodies (monoclonal and other), and their uses in nicotine and cotinine assays

Also Published As

Publication number Publication date
US11440970B2 (en) 2022-09-13
CN111432883B (zh) 2024-10-01
MX2020001725A (es) 2020-08-20
EP3668598B1 (en) 2025-07-30
KR20200089255A (ko) 2020-07-24
US20200377616A1 (en) 2020-12-03
AU2018317372A1 (en) 2020-03-05
WO2019036419A1 (en) 2019-02-21
EP4624496A2 (en) 2025-10-01
JP2020531480A (ja) 2020-11-05
KR102712005B1 (ko) 2024-09-30
EP4624496A3 (en) 2025-12-17
JP7364555B2 (ja) 2023-10-18
CA3072767A1 (en) 2019-02-21
CN111432883A (zh) 2020-07-17
ES3041362T3 (en) 2025-11-11
US20230089068A1 (en) 2023-03-23
BR112020002994A2 (pt) 2020-08-11
EP3668598A1 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
ES2974803T3 (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina y métodos para utilizarlos
Kosten et al. Immunotherapy for the treatment of drug abuse
De Villiers et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell
CN109952314A (zh) 治疗难治性偏头痛
LeSage et al. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies
Treweek et al. An antidote for acute cocaine toxicity
US20230089068A1 (en) Novel nicotine-binding antibodies
RS59354B1 (sr) Postupci lečenja nosne polipoze davanjem il-4r antagonista
Escobar-Chávez et al. Targeting nicotine addiction: the possibility of a therapeutic vaccine
Vocci et al. Vaccines against nicotine: how effective are they likely to be in preventing smoking?
Raleigh et al. Attenuating nicotine’s effects with high affinity human anti-nicotine monoclonal antibodies
CA2895702C (en) Heroin haptens, immunoconjugates and related uses
CN113474363A (zh) 用于降低体重和/或减少食物摄取量的gdf15类似物和方法
CN115698059A (zh) 使用抗bet v 1抗体治疗过敏的方法
US20220267474A1 (en) Methods for improving circulation and treating cardiovascular disease
JP2023550672A (ja) ポリオーマウイルス中和抗体の投薬
Pashmi Immunotherapy approach to combat nicotine addiction
TW202434632A (zh) 治療重症肌無力之方法
CN117120092A (zh) 用于治疗儿科重症肌无力的组合物和方法
HK40008538A (en) Treating refractory migraine
Roiko Passive immunization to treat nicotine dependence in rats
Cornish Enhancing the efficacy of a nicotine vaccine
Oliver Vaccination against cotinine as a potential approach to smoking cessation
HK1232129B (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ANTIDOTE THERAPEUTICS, INC.

Free format text: FORMER NAME(S): BLINK BIOMEDICAL; ANTIDOTE THERAPEUTICS, INC.; HENNEPIN HEALTHCARE RESEARCH INSTITUTE

Owner name: HENNEPIN HEALTHCARE RESEARCH INSTITUTE

Free format text: FORMER NAME(S): BLINK BIOMEDICAL; ANTIDOTE THERAPEUTICS, INC.; HENNEPIN HEALTHCARE RESEARCH INSTITUTE

Owner name: BLINK BIOMEDICAL SAS

Free format text: FORMER NAME(S): BLINK BIOMEDICAL; ANTIDOTE THERAPEUTICS, INC.; HENNEPIN HEALTHCARE RESEARCH INSTITUTE

FGA Letters patent sealed or granted (standard patent)